Ferroptosis regulation by SGLT2 inhibitors: mechanisms and clinical benefits in diabetic kidney disease

) axis. Furthermore, ferroptosis-related biomarkers in serum and urine display disease stage-dependent alterations, highlighting their potential utility for patient stratification and therapeutic response prediction. This review elucidates how SGLT2 inhibitors promote renal protection in DKD by regulating ferroptosis, supported by both mechanistic insights and clinical evidence. It also addresses unresolved issues in its current clinical application. Furthermore, this work proposes a promising pharmacological strategy for the prevention and treatment of DKD.